Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Company Background - The company has recently undergone leadership changes, with the current Executive Chairman, President, and CEO having been in the role for just over a year [2] - The CEO had previously retired but was drawn back into the industry due to the potential of the company and its technology [2] Technology and Innovation - The company possesses the ELUTYX technology, which is recognized as a leading long-acting platform for treating geographic atrophy, a significant area of interest for the CEO based on prior experience [3] - Independent evaluations confirmed the superiority of the ELUTYX technology, reinforcing its potential in the market [3] Regulatory Pathway - The company has established a Special Protocol Assessment (SPA) with the FDA, providing a clear regulatory pathway that aligns with the latest guidelines issued in February 2023 [4] - This regulatory clarity is seen as a major advantage for the company, facilitating its development and market entry [4] Market Opportunity - The CEO emphasizes the clinical need for more durable treatments with better outcomes, indicating a strong market opportunity for the company's offerings [4]